$INKT···bullish· highunknown Mink Therapeutics' iNKT platform could revolutionize immunotherapy at $50M market cap
iNKT cells combine innate and adaptive immunity, target lipid antigens independent of MHC, traffic natively to dense tumor stroma, and reboot both immune branches, creating a scal…